Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Orbital Marine Power aims to harness the energy flowing in tidal streams and rivers through its award-winning tidal turbines. Orbital's O2 turbine is designed to deliver enough power for up to 2,000 homes. The company's vision is to focus on providing turbines and services into a future £20 billion per annum utility-scale global market for clean and predictable power from tidal streams. Orbital is currently providing £15 million of funded design projects to refine its IP protected low carbon tidal technology in readiness to scale up and play its part in meeting the ever-increasing demand for clean power. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£2,595,231
Podcast Radio (PR) is the Ofcom-licensed UK digital broadcast radio station showcasing podcasts 24/7 globally. It is currently broadcasting in Surrey, Manchester, London, and Glasgow. Podcasting is expected to become a $3.3 billion industry by 2025. PR aims to be a disruptor in this segment. PR got front-page coverage in the international edition of Radio World magazine and has onboarded US radio Disc Jockey (DJ) Gene Baxter. The company will use 15% of the investment to secure digital radio broadcast transmission in 5 more UK cities by the end of 2020, 15% to partner with applicants for new digital radio transmitters, 15% to create a PR-led UK marketing campaign supported by social media, 25% to recruit new staff members, 10% to develop its on-air content, 10% to develop its website and application, and 10% to build new business partnerships to drive the international expansion of the company.
days to go:
Expired
investment:
£149,023
Toraphene is an environmental technology company that aims to eliminate plastic waste. It has released with its product, Toraphene, to solve this crisis. It claims that Toraphene is a biodegradable, compostable and commercially-viable plastic packaging substitute for conventional plastic. The company asserts that its product is biodegradable even in the ocean, and has been developed using graphene technology. It is focussed on eliminating carrier bags and food containers in its first-round which account for 23% of marine waste. It aims to be a segment leader in the projected $25.4 billion biodegradable plastic industry by 2026. The company will use the investment to make Toraphene accessible to companies worldwide and make plastic packaging obsolete.
days to go:
Expired
investment:
£1,000,000
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Propetly is an online platform that acts as a connecting hub between investment providers and global investors in the field of real estate. It enables potential property investors to find, evaluate and calculate their investment project within minutes. With the help of AI-enabled architecture, Propetly can verify transactions on its portal, suggest finance options and ensure complete diligence of the transaction as per industry benchmarks. Given the relative lack of professional and up-to-date property investors in the UK, Propetly aims to become the one-stop-shop for all real estate deals. Its offering has led to Propetly being counted amongst leading PropTech brands in the UK. With the funds received, Propetly will invest in paid advertising and PR, upgrade its AI systems to enable more options are available to customers across wide demographics and human resources.
days to go:
Expired
investment:
£235,079
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Square Mile Farms (SMF) is a company that installs innovative and productive vertical farms in a workplace to engage employees and help businesses create a culture of healthy, low-impact living. Its 'Office Farming' model creates green spaces for engagement and collaboration. In 2019, it was invited to build a vertical farm in Paddington Central by British Land, one of UK’s largest landowners. The setup now acts as a hub for the company's office farm installations and a base from which it can conduct Research and Development (R&D). SMF's customers include Grosvenor Group Limited and Vodafone. Moreover, the company has been covered by media platforms such as BBC One and BBC Radio. It will use 45% of the investment for sales and business development, 15% for design and technology up-gradation, 15% for raising its profile and increasing brand awareness, and 25% for operations.
days to go:
Expired
investment:
£504,118
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.
days to go:
Expired
investment:
£445,814
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
